Table 2.
HTA reports of biosimilars by organisations, countries of origin and type of reports
| HTA organisation | Country of HTA organisation | Full-HTA (n = 2) |
Mini-HTA (n = 4) |
Rapid reviews (n = 64) |
|---|---|---|---|---|
| HAS | France | 0 | 0 | 31 |
| CADTH | Canada | 0 | 3 | 9 |
| INESSS | Canada | 1 | 1 | 7 |
| NIHR HC | United Kingdom | 0 | 0 | 3 |
| NICE | United Kingdom | 1 | 0 | 1 |
| RER | Italy | 0 | 0 | 4 |
| Veneto CRUF | Italy | 0 | 0 | 1 |
| AQuaAS | Spain | 0 | 0 | 2 |
| TLV | Sweden | 0 | 0 | 1 |
| AHTAPol | Poland | 0 | 0 | 1 |
| ACE | Singapore | 0 | 0 | 2 |
| ICER | United States | 0 | 0 | 1 |
| IECS | Argentine | 0 | 0 | 1 |
ACE Agency for Care Effectiveness; AHTAPol Agencja Oceny Technologii Medycznych; AQuaAS Agència de Qualitat i Avaluació Sanitàries de Catalunya; CADTH Canadian Agency for Drugs and Technologies in Health; HAS Haute Autorité de Santé; HTA health technology assessment; ICER Institute for Clinical and Economic Review; IECS Instituto de Efectividad Clinica Sanitaria; INESSS Institut national d’excellence en santé et en services; NICE National Institute for Health and Care Excellence; NIHR HC The National Institute for Health Research Horizon Scanning Centre; RER Regione Emilia-Romagna; TLV Dental and Pharmaceutical Benefits Agency; Veneto CRUF Regione del Veneto, Coordinamento Regionale Unico sul Farmaco